A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2014
Price : $35 *
At a glance
- Drugs PF 5231023 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 18 Mar 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 08 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.